Clinical Trials
Search our team at AdventHealth Research Institute
Showing 1 - 11 of 11 clinical trials matching your search
-
NCT07188558
A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, An Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Product Candidate, verses Investigator’s Choice of CD19 CAR T-Cell Therapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Second-Line Setting (PiNACLE-H2H)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT06852222
75276617AML3001: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy (cAMeLot-2)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT06619561
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT06479165
KRT-232-115: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to determine if navtemadlin in combination with ruxolitinib is a well-tolerated and effective treatment for MF. -
NCT05442216
TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoWe are doing this study because we want to find out if this approach will provide a longer period of disease response and is safe. The researchers conducting this study plan to publish the... -
NCT06500273
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective... -
NCT05332054
Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoCaribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have... -
NCT05919511
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoDescribe the clinical course and burden of cGVHD after alloSCT. Describe personal and healthcare resource utilization associated with the management of cGVHD. Describe practice patterns and therapy... -
NCT05346835
68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT04245397
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.
